ClinicalTrials.gg
RecruitingNCT07001293MomMAUpdated May 7, 2026

Expectant Moms Managing Attention-Deficit/ Hyperactivity Disorder

An interventional study of MomMA Intervention and Treatment as Usual (TAU) in ADHD, Perinatal and Behavioral Intervention, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Attention Deficit Disorder with Hyperactivity by University of Pittsburgh — 2 open to participants now, 4 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · University of Pittsburgh.

Planned enrollment
4th of 10
80 · median 43
Started
2026
the only one that year
No phase
7 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Attention Deficit Disorder with Hyperactivity by University of Pittsburgh, this one is the 4th largest by planned enrollment, is the only one that started in 2026, is one of 7 with no phase, and was the 10th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

2 of the 10 studies in Attention Deficit Disorder with Hyperactivity by University of Pittsburgh are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Attention Deficit Disorder with Hyperactivity by University of Pittsburgh, or all of them as a file.
02

Study summary

The goal of this study is to test a behavioral program for pregnant individuals with ADHD. This behavioral program focuses on skills for managing ADHD and related symptoms in pregnancy and postpartum.

This pilot effectiveness-implementation trial aims to (1) preliminarily evaluate the MomMA behavioral intervention compared to treatment as usual (TAU) on clinical outcomes and (2) evaluate implementation outcomes, including feasibility and acceptability of clinic screening within existing OB workflows; assessment and intervention protocols; provider training/fidelity to manual; and all other study protocols from the perspective of real-world providers and participants.

Read the detailed description

Treating pregnant individuals with ADHD may improve parent and child wellbeing, parent-child interactions, and psychosocial familial factors to enhance family resilience and reduce prevalence/severity of child mental health disorders. The current study will test the MomMA (Moms Managing ADHD) intervention and implement it via a randomized controlled trial (N= 40 pregnant women with ADHD; 20 receiving the behavioral intervention and 20 receiving TAU), delivered by women's health behavioral therapists. Investigators will examine treatment acceptability, feasibility, and appropriateness, as well as implementation factors (fidelity, adherence, facilitators/barriers). In addition, quantitative data will be used to assess parent and child clinical outcomes, including maternal ADHD symptom severity and impairment (primary), parent-child attachment, and infant temperament/behavior. Finally, changes in target mechanisms (executive function and emotion regulation) and whether changes in the target are associated with change in clinical outcomes will be explored.

03

Conditions studied

  • ADHD
  • Perinatal
  • Behavioral Intervention

Keywords

  • ADHD
  • Pregnancy
  • Perinatal Mental Health
  • Behavioral Intervention
  • Parenting
  • Emotion Regulation
  • Executive Functioning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. meets full criteria for ADHD
  2. is between 14- and 22-weeks of gestation
  3. 18 years of age or older
  4. English speaking
  5. Lives in Pennsylvania

Exclusion criteria

Exclusion Criteria:

  1. substance use disorders requiring dual diagnosis treatment
  2. intellectual disability
  3. bipolar disorder, psychosis, and major depressive disorder with suicidal ideation
  4. the following high complexity medical conditions during pregnancy: maternal cancer, multiples, placenta accreta, and/or fetus known to have a severe congenital condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    MomMA Intervention

    Behavioral: MomMA Intervention

  • Other
    Treatment As Usual (TAU)

    Treatment will be determined by participant and their medical and behavioral health providers.

    Other: Treatment as Usual (TAU)

Interventions

  • BehavioralMomMA Intervention

    The MomMA program is a CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings.

  • OtherTreatment as Usual (TAU)

    Participants will receive treatment as usual, including but not limited to medication and behavioral therapy. No participation in treatment is required.

06

What researchers measure

Primary outcomes

  1. Intervention Acceptability

    Therapist and participant report of intervention acceptability will be assessed using the 4-item Acceptability of Intervention Measure (AIM), rated from rated from 1 (completely disagree) to 5 (completely agree).

    Time frame: Post Intervention (36 weeks gestational age)

  2. Intervention Feasibility

    Therapist and participant report of intervention feasibility will be assessed using the 4-item Feasibility of Intervention Measure (FIM), rated from 1 (completely disagree) to 5 (completely agree).

    Time frame: Post Intervention (36 weeks gestational age)

  3. Intervention Appropriateness

    Therapist and participant report of intervention appropriateness will be assessed using the 4-item Intervention Appropriateness Measure (IAM), rated from 1 (completely disagree) to 5 (completely agree).

    Time frame: Post Intervention (36 weeks gestational age)

  4. ADHD Symptom Severity

    Number and severity of ADHD symptoms will be self-reported using the Barkley Adult ADHD Rating Scale-IV (BAARS-IV). Number and severity of ADHD symptoms will be self-reported using the Barkley Adult ADHD Rating Scale-IV (BARRS-IV). Total score (range 18-72) and number of symptoms (0-18) will be determined by summing the Inattention (total score: range 9-36; number of symptoms: range 0-9), Hyperactivity (total score: range 5-20; number of symptoms: range 0-5), and Impulsivity (total score: range 4-16; number of symptoms: range 0-4) subscales. On all scales, higher scores indicate greater ADHD symptoms.

    Time frame: Post Intervention (36 weeks gestational age) and Postpartum follow-up (4-5 months postpartum)

  5. ADHD Functional Impairment

    Impairment in family functioning and self-concept will be assessed on two subscales of the Weiss Functional Impairment Rating Scale (WFIRS-S). Impairment in family functioning and self-concept will be assessed on two subscales of the Weiss Functional Impairment Rating Scale (WFIRS-S). For each scale, mean impairment (range 0-3) and a total impairment score (Family subscale: range 0-24; Self-Concept subscale: range 0-15) will be calculated. Any subscale with at least 2 items scored a 2 or 3, one item scored 3, or a mean score of \>1.5 is considered impaired.

    Time frame: Post Intervention (36 weeks gestational age) and Postpartum follow-up (4-5 months postpartum)

  6. Perinatal Mood/Distress

    Symptoms of depression, anxiety, and distress will be assessed using self-report on the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder scale (GAD-7), and Perceived Stress Scale (PSS). Symptoms of depression, anxiety, and distress will be assessed using self-report on the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder scale (GAD-7), and Perceived Stress Scale (PSS). The PHQ-9 (total score range 0-27) measures depression, with higher scores indicating greater depressive symptoms. The GAD-7 (total score range 0-21) measures anxiety, with higher scores indicating greater anxiety symptoms. The PSS (total score range 0-40) measures perceived stress, with higher scores indicating greater perceived stress.

    Time frame: Post Intervention (36 weeks gestational age) and Postpartum follow-up (4-5 months postpartum)

Secondary outcomes

  1. Attachment

    Maternal Postnatal Attachment Scale (MPAS) is a 19-item self-report questionnaire, and measures Mother to Baby Attachment during pregnancy. Questions explore maternal interest in and preoccupation with pregnancy, as well as the respondent's emotions towards the growing infant. Similar to the MPAS, each item is equally weighted and has five answer choices, with total scores ranging from 19-95.

    Time frame: Postpartum follow-up (4-5 months postpartum)

  2. Home Environment

    Using the Confusion, Hubbub, and Order Scale, a 15-item self-report scale rated from 1 (Very much like your own home) to 4 (Not at all like your own home). Total scores range from 15-60, with higher scores indicating more chaotic homes.

    Time frame: Postpartum follow-up (4-5 months postpartum)

  3. Infant Behavior

    Infant behavior (temperament and sleep) will be reported by mothers on the Infant Behavior Questionnaire-Short Form (IBQ-R-SF) and the Brief Infant Sleep Questionnaire (BISQ).

    Time frame: Postpartum follow-up (4-5 months postpartum)

  4. Parent-Child Interaction

    Parent affect, warmth, responsiveness, engagement, sensitivity, indifference, intrusiveness, and infant affect, engagement, attentiveness will be rated using the Global Ratings of Mother-Infant Interaction.

    Time frame: Postpartum follow-up (4-5 months postpartum)

Other outcomes

  1. Parent Executive Function

    Participant will self-report on executive function using the Barkley Deficits in Executive Function Scale (BDEFS). Items are rated from 1 (Never or rarely) to 4 (Very often). Executive Functioning will be assessed as a Target Mechanism. These data will be used in exploratory analyses to determine change from baseline to post-intervention, and whether this change is related to change in clinical outcome measures.

    Time frame: Change from baseline to Post Intervention (36 weeks gestational age)

  2. Parent Emotion Regulation

    Participant will self-report on executive function using the Difficulties in Emotion Regulation Scale - Short Form (DERS-SF). Items are rated from 1 (Almost never, 0-10%) to 5 (Almost always, 91-100%). Emotion Regulation will be assessed as a Target Mechanism. These data will be used in exploratory analyses to determine change from baseline to post-intervention, and whether this change is related to change in clinical outcome measures.

    Time frame: Change from Baseline to Post Intervention (36 weeks gestational age)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chronis-Tuscano A, Clarke TL, O'Brien KA, Raggi VL, Diaz Y, Mintz AD, Rooney ME, Knight LA, Seymour KE, Thomas SR, Seeley J, Kosty D, Lewinsohn P. Development and preliminary evaluation of an integrated treatment targeting parenting and depressive symptoms in mothers of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol. 2013 Oct;81(5):918-25. doi: 10.1037/a0032112. Epub 2013 Mar 11. PubMed 23477479 ↗
  • Joseph HM, Khetarpal SK, Wilson MA, Molina BSG. Parent ADHD Is Associated With Greater Parenting Distress in the First Year Postpartum. J Atten Disord. 2022 Jul;26(9):1257-1268. doi: 10.1177/10870547211066488. Epub 2021 Dec 23. PubMed 34937412 ↗

Individual participant data

Plan to share: Yes — Individual participant data collected during the trial will be shared, after deidentification, via the NIMH National Data Archive.

Time frame: Data will be shared upon publication or 1 year after the grant end date. Data will be available indefinitely.

Data sharing details ↗ · nda.nih.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 25 months is close to that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Jun 3, 2025
StartActual
Apr 26, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001293
Collaborators
University of Maryland, College Park
Responsible party
Heather Joseph (Assistant Professor of Psychiatry and Pediatrics, University of Pittsburgh) — Principal investigator
First posted
Jun 3, 2025
Start date
Apr 26, 2026
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
May 7, 2026

Study contacts

Michelle Wilson, Research Coordinator
Contact
wilsonm13@upmc.edu
412-420-8309
Heather M Joseph, DO Assistant Professor of Psychiatry and Pediatrics
principal investigator · University of Pittsburgh
Andrea Chronis-Tuscano, PhD Joel & Kim Feller Endowed Professor
principal investigator · University of Maryland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion